AtriCure, Inc. (ATRC) Financials

NASDAQ:ATRC

Market Cap

2.06B

Total Revenue

330.38M

Gross Profit

245.94M

Operating Income

-42.67M

Net Income

-46.47M

Metric	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
revenue	81,889,000	107,454,000	129,755,000	155,109,000	174,716,000	201,630,000	230,807,000	206,531,000	274,329,000	330,379,000
costOfRevenue	22,326,000	31,704,000	36,880,000	44,008,000	48,553,000	54,510,000	60,472,000	57,222,000	68,469,000	84,439,000
grossProfit	59,563,000	75,750,000	92,875,000	111,101,000	126,163,000	147,120,000	170,335,000	149,309,000	205,860,000	245,940,000
researchAndDevelopmentExpenses	13,440,000	18,600,000	25,742,000	35,824,000	34,144,000	34,723,000	41,230,000	43,070,000	48,506,000	57,337,000
sellingAndMarketingExpenses	--	--	--	--	--	--	--	--	--	--
generalAndAdministrativeExpenses	57,014,000	73,510,000	93,853,000	106,415,000	116,998,000	129,524,000	--	--	--	--
sellingGeneralAndAdministrativeExpenses	57,014,000	73,510,000	93,853,000	106,415,000	116,998,000	129,524,000	162,227,000	150,472,000	204,649,000	231,272,000
operatingExpenses	70,454,000	92,110,000	119,595,000	142,239,000	151,142,000	164,247,000	203,457,000	193,542,000	253,155,000	288,609,000
operatingIncome	-10,891,000	-16,360,000	-26,720,000	-31,138,000	-24,979,000	-17,127,000	-33,122,000	-44,233,000	-47,295,000	-42,669,000
totalOtherIncomeExpensesNet	-553,000	182,000	-456,000	-2,160,000	-1,899,000	-3,784,000	-1,873,000	-3,808,000	97,682,000	-3,529,000
ebitda	-8,871,000	-11,586,000	-20,442,000	-21,839,000	-15,851,000	-8,373,000	-23,756,000	-44,233,000	-149,795,000	-42,669,000
depreciationAndAmortization	2,020,000	4,774,000	6,278,000	9,299,000	9,128,000	8,754,000	9,366,000	9,548,000	-102,500,000	11,710,000
interestIncome	16,000	96,000	190,000	227,000	227,000	1,006,000	2,398,000	1,101,000	466,000	1,994,000
interestExpense	566,000	305,000	292,000	1,801,000	2,264,000	4,607,000	4,111,000	4,885,000	4,918,000	4,986,000
incomeBeforeTax	-11,444,000	-16,178,000	-27,176,000	-33,298,000	-26,878,000	-20,911,000	-34,995,000	-48,041,000	50,387,000	-46,198,000
incomeTaxExpense	18,000	33,000	36,000	40,000	14,000	226,000	199,000	114,000	188,000	268,000
netIncome	-11,462,000	-16,211,000	-27,212,000	-33,338,000	-26,892,000	-21,137,000	-35,194,000	-48,155,000	50,199,000	-46,466,000
eps	-0.56	-0.61	-0.97	-1.05	-0.83	-0.62	-0.94	-1.14	1.11	-1.02
epsdiluted	-0.56	-0.61	-0.97	-1.05	-0.83	-0.62	-0.94	-1.14	1.09	-1.02
weightedAverageShsOut	20,431,000	26,374,000	28,058,000	31,609,000	32,387,000	34,087,000	37,589,000	42,125,000	45,066,000	45,740,000
weightedAverageShsOutDil	20,431,000	26,374,000	28,058,000	31,609,000	32,387,000	34,087,000	37,589,000	42,125,000	46,039,000	45,740,000
costAndExpenses	92,780,000	123,814,000	156,475,000	186,247,000	199,695,000	218,757,000	263,929,000	250,764,000	321,624,000	373,048,000
otherExpenses	-553,000	182,000	-456,000	-2,160,000	-1,899,000	-3,784,000	-1,873,000	-3,808,000	-4,818,000	-3,529,000

Key Facts

Industry

Medical Instruments & Supplies

Sector

Healthcare

Headquarters

Mason, OH, US

Website

atricure.com

CEO

Mr. Michael H. Carrel

Employees

1050

About the Company

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.